Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-11-08
2005-11-08
Nickol, Gary (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S388100
Reexamination Certificate
active
06962980
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.
REFERENCES:
patent: 6468546 (2002-10-01), Mitcham et al.
patent: WO 99/25877 (1999-05-01), None
patent: WO 9963088 (1999-12-01), None
patent: WO9963088 (1999-12-01), None
patent: WO 00/12758 (2000-03-01), None
patent: WO 00/36107 (2000-06-01), None
patent: WO 00/55629 (2000-09-01), None
patent: EP 1033401 (2000-09-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/76531 (2000-12-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/18542 (2001-03-01), None
patent: WO 01/40269 (2001-06-01), None
patent: WO 01/57272 (2001-08-01), None
patent: WO 01/94641 (2001-12-01), None
patent: WO 02/02587 (2002-01-01), None
patent: WO 02/02624 (2002-01-01), None
patent: WO 02/10187 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/16581 (2002-02-01), None
Hovig, E. et al., “CA 125: The End of the Beginning,”Tumor Biology22: 345-347, 2001.
O'Brien, T.J. et al., “The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure,”Tumor Biology23:154-169, 2002.
O'Brien, T.J. et al., “The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences,”Tumor Biology22: 348-366, 2001.
Schummer, M. et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,”Gene238: 375-385, 1999.
Whitehouse, C. et al., “NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube,”Eur. J. Biochem.269: 538-545, 2002.
Yin and Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16,”Journal of Biological Chemistry276 (29): 27371-27375, Jul. 20, 2001.
Yin, B.W.T. et al., “Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene,”International Journal of Cancer98: 737-740, 2002.
Bookman et al., “Biological therapy of ovarian cancer: Current directions,”Seminars in Oncology,25 (3):381-396, 1998.
Gillespie et al., “Mage, Bage, and Gage: Tumour antigen expression in benign and malignant ovarian tissue,”British Journal of Cancer,78 (6):816-821, Sep. 1998.
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,”Proc. Natl. Acad. Sci. USA94: 2150-2155, Mar. 1997.
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro,”DNA Res.,5:169-176, 1998.
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1,”Cell93: 81-91, Apr. 3, 1998.
Köhler et al., “Immunotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,”Gebrutshilfe und Fraenheilkunde,58 (4):180-186, Apr. 1998 + (English Abstract).
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,”Journal of Pharmaceutical Sciences,87 (11):1375-1378, Nov. 1998.
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,”The Journal of Immunology152 (1):163-175, Jan. 1, 1994.
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,”Annals of Surgical Oncology,5 (8):743-750, Dec. 1998.
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci.93: 10614-10619, Oct. 1996.
Frankel, A.E. et al., “Targeted Toxins,”Clinical Cancer Research6: 326-334, Feb. 2000.
GenBank Accession No. AA075632, Dec. 23, 1997. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. AA404225, Aug. 8, 1997. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. NM_024626, Sep. 3, 2004. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. NP_078902, Sep. 3, 2004. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. XM_018334, Oct. 16, 2001. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. XP_018334, Oct. 16, 2001. Available at www.ncbi.nlm.nih.gov/entrz .
Algate Paul A.
King Gordon E.
Mitcham Jennifer L.
Corixa Corporation
Fetterolf Brandon
Nickol Gary
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505338